Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Antibody-drug conjugates (ADCs) have emerged as a revolutionary therapeutic class,
combining the precise targeting ability of monoclonal antibodies with the potent cytotoxic …

The treatment of cancer patients has dramatically changed over the past decades with the
advent of monoclonal antibodies, immune-checkpoint inhibitors, bispecific antibodies, and …

In the past decade, significant progress was made in treating hormone receptor-positive
(HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast …

Abstract Background Antibody drug conjugates (ADCs) represent a revolutionary drug class
in cancer therapy, combining the precision of targeted therapy with the cytotoxic effects of …

Opinion statement Antibody drug-conjugates (ADCs) have revolutionized the treatment of
many types of cancer, including breast cancer. Recently, two new ADCs have been …

TROP2 antibody drug conjugates (ADCs) are under active development. We seek to
determine whether we can enhance activity of TROP2 ADCs by increasing TROP2 …

For decades, chemotherapy has been the mainstay of breast cancer treatment. Novel
therapies are expanding the therapeutic options and altering the treatment algorithms to …

Antibody–drug conjugates (ADC) represent a fast-growing drug class in oncology. However,
ADCs are associated with resistance, and therapies able to overcome it are of utmost …

Abstract Background Nectin-4 and Trop-2 are transmembrane targets of FDA-approved
antibody-drug conjugates (ADC) Enfortumab-vedotin (EV) and Sacituzumab govitecan (SG) …